Researchers found that blocking glycolysis makes cancer cells more susceptible to death by starvation, potentially enhancing the effectiveness of taxol. This breakthrough could lead to new therapies against various cancers.
A CNIO team has identified the origin of damage to induced pluripotent stem cells and developed strategies to reduce it, resulting in cells with less damage to their genome. This breakthrough improves the safety of iPS cells for use in biomedicine, potentially treating cardiovascular diseases, diabetes, and neurodegenerative disorders.
Telomeres, protective caps on chromosome ends, have been linked to numerous illnesses, including many types of cancer. Their shortening is associated with ageing and tissue regeneration issues, but cancer cells can repair them using telomerase.
CNIO researchers discover that telomeres are at the origin of idiopathic pulmonary fibrosis, a disease with no current treatment. The study reveals that telomere damage triggers progressive pulmonary fibrosis in mice, suggesting new therapeutic strategies based on telomerase activation.
Researchers from CNIO have discovered a new approach to fighting cancer by targeting telomeres and blocking the TRF1 gene. This method shows dramatic improvements in mice with lung cancer, with minimal toxic effects, offering a promising therapeutic target for cancer therapy.
Researchers have discovered that telomeres are essential for the renewal of plant stem cells and growth. The study uses innovative technology to measure telomeres at the cellular level in plants, revealing a vital relationship between telomere length, stem cells, and longevity. This breakthrough has implications for developing novel th...
Despite recent advances in understanding pancreatic cancer biology, researchers have made little progress in finding effective treatments. However, a new review suggests that immunotherapy combined with other treatments may significantly increase patient survival rates, and could lead to new therapeutic strategies.
Researchers created a mouse model showing telomere dysfunction triggers liver damage, including cirrhosis and hepatitis. Telomeres protect genetic data, but their dysfunction leads to disease.
Researchers from CNIO have discovered that the MCRS1 protein induces increased mTOR activity in response to excess nutrients, leading to cell growth and proliferation. This correlation was found in human colorectal cancer samples, suggesting a potential link between MCRS1 activity and disease prognosis.
A CNIO team has developed a method to rescue premature aging in mice by increasing the body's capacity to produce DNA building blocks. By introducing a mutation that boosts nucleotide production, the researchers doubled the lifespan of ATR-mutant mice from 24 weeks to 50 weeks, also alleviating symptoms of Seckel syndrome.
Researchers at CNIO have discovered a new gene, MDH2, linked to rare neuroendocrine tumors with high hereditary risk. The finding confirms the relationship between metabolism and tumour development, providing a boost to genetic diagnosis and potential metastasis prevention.
Researchers from CNIO have developed a new anti-obesity treatment that reduces body weight and improves metabolic syndrome symptoms in obese mice and monkeys. The treatment, CNIO-PI3Ki, selectively targets the storage of nutrients in excess, leading to weight loss without affecting other tissues or brain function.
Researchers found that non-mutated CLL shows increased gene expression variability, while mutated leukaemia has lower variability. This variation is linked to tumour aggressiveness and may help predict disease subtype.
Scientists have made the largest ever catalogue of biological chimeras available to the public domain. The new database comprises over 29,000 small RNA molecules that originate from different genomic regions, which could reveal useful markers for clinical oncology practice and novel drug targets for cancer treatment.
Researchers at CNIO have discovered a new way to produce platelets artificially, reprogramming megakaryocytes to increase in size. This breakthrough could lead to the development of new treatments for thrombocytopenia and cancer by targeting specific proteins involved in cell growth.
Researchers at CNIO have identified a key regulator of keratinocyte differentiation, Fra-2, which plays a crucial role in the formation of human skin. The study reveals that activation of Fra-2 induces premature differentiation and may hold promise for treating skin diseases.
Researchers have identified genetic markers associated with severe neurological toxicity in patients treated with paclitaxel, a highly effective but toxic chemotherapeutic drug. The study found that specific genetic variants can lead to reduced drug excretion and increased toxicity, allowing for personalized treatment risk assessment.
Researchers at CNIO discovered that Notch genes act as tumour suppressors in bladder cancer, clarifying their role and providing clues for understanding their dual function. The study cautions against using therapeutic strategies based on Notch deactivation due to potential increased risk of developing squamous-type tumours.
Researchers at CNIO have discovered that macrophages, a type of immune cell, play a key role in activating hair follicle stem cells, promoting hair growth. This breakthrough could lead to the development of novel treatment strategies for hair loss and has broader implications for skin regeneration and cancer research.
Researchers at CNIO have developed a gene therapy that reactivates the telomerase gene only in the heart of adult mice, resulting in increased survival rates and regeneration of cardiomyocytes. This study provides proof-of-concept for treating chronic and acute heart failure and opens new avenues for age-related diseases.
Scientists have developed a method to observe DNA double strand breaks, a process that lasts microseconds. They also created slow-motion films of the reaction by altering temperature and pH balance.
Researchers from CNIO discovered that a derivative of vitamin B3, nicotinamide riboside, prevents the development of liver tumors and induces tumor regression in mice. The study suggests that boosting NAD+ levels may have beneficial effects on cancer.
Conventional treatments such as surgery and radiotherapy are less effective in prostate cancer patients carrying BRCA mutations, resulting in lower survival rates. The study suggests that targeted therapy, like PARP inhibitors, may be a more suitable option for these patients.
Researchers found that the current classification system for colorectal cancer cannot be used to predict drug responses to FOLFIRI. The study suggests that a new approach is needed to make informed treatment decisions.
Researchers at CNIO have developed a mouse model that expresses the most common K-Ras mutation found in Noonan patients, reproducing its most representative features. The study aims to advance knowledge of the syndrome and develop specific treatments for each mutation.
CNIO researchers found that the simultaneous inhibition of Cdk4 and Cdk6 is more effective than individual inhibition in reducing tumour growth and promoting aggressive tumours in mice. The study also revealed that the combined activation of both oncogenes leads to uncontrolled cell division and an increased risk of developing leukemia.
Researchers from CNIO have characterized a key protein interaction that regulates cellular proliferation; this discovery may aid in developing new anti-microtubule drugs to combat cancer. The study's findings provide insights into the molecular basis of microtubule assembly during cell division.
Researchers from CNIO have identified a new marker for cancer stem cells using riboflavin, a pigment that emits green fluorescence. This discovery enables the tracking of cancer stem cells in tumors, which are responsible for chemical resistance and tumor growth.
The Phase I Clinical Trial of nintedanib combined with paclitaxel showed a 50% complete response rate in early HER-2-negative breast cancer patients. The study's results have validated the safety and efficacy of the drug combination, paving the way for a large-scale Phase II Clinical Trial.
Researchers have identified the specific chromosomes where telomere-protecting RNAs (TERRAs) originate from. The study reveals that TERRAs exclusively come from chromosome 18 and to a lesser extent from chromosome 9. This discovery will help design tools to study their role in telomere biology and disease.
A recent study identifies rare variants in the APOB gene in families with exceptional longevity, highlighting its potential role in lipid transport and cholesterol metabolism. The findings suggest that genetic factors influencing lipid metabolism may contribute to human longevity.
Researchers have found that cachexia, associated with cancer, is triggered by the conversion of white fat to brown fat tissue, a process also studied for obesity and diabetes. Blocking inflammation-promoting cytokine IL-6 can reduce cachexia symptoms.
CNIO researchers identify Sox4 as a crucial gene in tissue maintenance, with implications for aging and cancer. Mice deficient in Sox4 exhibit accelerated aging, osteoporosis and age-related illnesses but resist cancer development.
Manuel Serrano proposes a new vision of cellular senescence as a mechanism to eliminate unwanted cells and promote tissue regeneration. Recent research reveals that senescence is not intrinsically negative for the organism, but rather a protective mechanism against cell damage.
Researchers at CNIO discover that NANOG gene is active in adult organisms, regulating cell division in stratified epithelia. Blocking NANOG action reduces tumour cell proliferation, highlighting its role in cancerous cells.
A CNIO team updates the number of human protein-coding genes to 19,000, with almost all having ancestors prior to primate evolution. The study suggests that differences between humans and primates are small, and complexity lies in gene regulation and non-coding regions.
Researchers at the Spanish National Cancer Research Centre (CNIO) have discovered over 40 genes that predict melanoma aggressiveness and distinguish it from other cancers with poor prognoses. These genes are involved in the formation of endosomes, which play a crucial role in tumor cell behavior.
New mutations in cohesin proteins are common in various cancers, including bladder cancer and melanoma. Cohesin regulates cell division and DNA repair, making it a potential driver or facilitator for tumours.
Researchers from CNIO and CNIC successfully reproduced chromosomal translocations in human stem cells, identical to those found in patients with acute myeloid leukemia and Ewing's sarcoma. This breakthrough allows for the study of new therapeutic targets and experimental recapitulation of tumour development.
Researchers at CNIO developed a new strategy to personalize cancer therapies for advanced patients by analyzing genetic mutations and testing drugs in 'Avatar' mice. The study showed clinical responses in up to 77% of patients, providing a promising approach for personalized medicine.
A study reveals that SIRT1 is required for correct and safe cell reprogramming, ensuring healthy functioning of induced pluripotent stem cells. The protein helps maintain telomeres and prevents chromosome aberrations and DNA damage.
Researchers discovered two new genes, NEIL2 and OGG1, that modulate the risk of breast and ovarian cancer in women with high-risk mutations. The genes affect an alternative DNA repair pathway and may have implications for treatments like PARP inhibitors.
Researchers at CNIO have identified two novel treatments for psoriasis, one targeting S100A9 and the other inhibiting miR-21, which show promise in reducing side effects. These discoveries offer new hope for patients suffering from this chronic disease.
A study published in PLOS Genetics reveals that nearly 100 genes may explain the lower cancer incidence rate in patients with central nervous system diseases. Researchers found that specific genes were inversely activated in both diseases, suggesting a protective effect against cancer.
Researchers at CNIO propose a new combined therapy to treat cancer by combining etoposide with compounds that interfere with the cell cycle, increasing specificity and improving the therapeutic window. This approach aims to reduce toxicity and increase effectiveness in treating tumour cells.
Researchers at CNIO discovered a connection between microtubules and cell-cell junctions that holds skin stem cells together to support skin architecture. This finding sheds light on the importance of cellular components in maintaining skin function and may lead to new regenerative or anti-cancer therapies.
A research team at CNIO has identified AP-1 proteins as key regulators of fatty liver disease (FLD), a condition that affects up to 30% of adults in Western societies. Increased expression of these proteins can prevent fat accumulation and FLD in mice.
Researchers at CNIO demonstrate that cells from various tissues can be converted into embryonic stem cells using Shinya Yamanaka's technique, exhibiting higher plasticity than existing iPSCs.
Researchers at CNIO discovered blocking Cdh1 protein prevents cellular proliferation in rapidly dividing cells. This could lead to new therapies targeting cancer.
Researchers at CNIO have created a massive database of interactions between drugs and proteins, known as FireDB. The database includes over 16,600 compounds and 500,000 interactions, providing valuable information for the study of cancer and therapeutic agents.